Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial

In BOLERO‐2, adding everolimus to exemestane resulted in a twofold increase in median progression‐free survival (PFS) vs exemestane in postmenopausal women with hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negative (HER2−) advanced breast cancer (aBC) after progression o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2019-02, Vol.144 (4), p.877-885
Hauptverfasser:	Tesch, Hans, Stoetzer, Oliver, Decker, Thomas, Kurbacher, Christian M., Marmé, Frederik, Schneeweiss, Andreas, Mundhenke, Christoph, Distelrath, Andrea, Fasching, Peter A., Lux, Michael P., Lüftner, Diana, Hadji, Peyman, Janni, Wolfgang, Muth, Mathias, Kreuzeder, Julia, Quiering, Claudia, Taran, Florin‐Andrei
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult advanced breast cancer Aged Aged, 80 and over Androstadienes - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aromatase Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer Cancer Therapy and Prevention Chemotherapy Dyspnea Epidermal growth factor ErbB-2 protein estrogen receptor‐positive everolimus Everolimus - administration & dosage exemestane Female HER2‐negative Hormone replacement therapy Humans Inhibitor drugs Kaplan-Meier Estimate Medical research Metastases Middle Aged Neoplasm Metastasis Outcome Assessment (Health Care) - methods Outcome Assessment (Health Care) - statistics & numerical data Patients Post-menopause Postmenopause Quality of life Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Respiration Safety Stomatitis Survival Targeted cancer therapy Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!